Supplementary Materials and Methods
cells/well in a volume of 150 µl/well of culture medium in 96-well plates coated with 1.5% agarose in basal medium. Solid tumor spheroids formed within approximately 24-48 h after initial seeding (d0) and were used in functional assays. For tumor spheroid growth curves, phase contrast pictures of independent solid spheroids were analyzed for each condition from six independent experiments by Fiji software (2) .
Tumor Spheroid Infiltration of NK Cell Subpopulations
For infiltration studies with NK cell subpopulations, primary human NK cells on d7 of culture were stained with anti-human CD56 (clone B159; BD Bioscience, USA) and sorted on a FACS ARIAII instrument (BD Bioscience, USA) for CD56 bright and CD56 dim subpopulations. Solid FaDu tumor spheroids were co-cultured at an E:T of 1:1 with the individual NK cell subpopulations for 48 h. For histology, individual spheroids (n > 8) were collected and embedded into OCT compound (Sakura, Japan). Cryosections were stained with mouse anti-human CD45 (clone 2B11+PD7/26; DAKO, Germany) and analyzed by standard two-step polymer methods with Envision kits (DAKO, Germany). For counterstaining, Hematoxylin (DAKO, Germany) was used according to manufacturer's instructions.
Cytotoxicity Assays with NKG2D Blocking Antibodies
For blocking experiments, NK cells were pre-incubated with mouse anti-human NKG2D antibodies (MAB139; R&D Systems, USA) for 30 minutes prior to co-incubation with CFSE-labeled HNSCC (co-incubation for 16 h) and SiHa (co-incubation for 2 h) cell lines at appropriate effector-to-target (E:T) ratios in NK cell medium without IL-2. NK cells were labeled with mouse anti-human CD45-APC antibodies (clone 5B1; Miltenyi Biotec, Germany) and live/dead cell discrimination was achieved by staining with SytoxBlue (Life Technologies, USA) prior to the measurement on a BD FACSCanto II instrument equipped with a 96-well plate HTS Sampler. Cellular event counts were analyzed with FlowJo software. The percentage of cell lysis was calculated by evaluation of viable (CFSE + /SytoxBlue -) and dead (CFSE + /SytoxBlue + ) target cells. Data is represented as mean ± SEM of triplicates. Statistical significance was determined by one-way ANOVA.
Flow Cytometry of Tumor Spheroids
For detection of NKG2DLs, TrypLE TM Express-treated (Life Technologies, USA) tumor spheroids were stained with mouse monoclonal antibodies: mouse anti-human MICA (clone AMO1) (3)), mouse anti-human MICB (MAB1599), mouse anti-human ULBP1 (MAB1380), mouse anti-human ULBP2 (MAB1298) and mouse anti-human ULBP3 (MAB1517; all R&D Systems, USA). Rat anti-mouse IgG 1 -APC (130-095-902; Miltenyi Biotec, Germany) or antimouse IgG 2a/b -APC (130-095-880; Miltenyi Biotec, Germany) served as secondary antibodies. As negative control, samples incubated with secondary antibodies only were used. Cells were measured on a FACSCanto II instrument equipped with a 96-well plate HTS Sampler (BD Bioscience, USA) and analyzed with FlowJo software (Tree Star, USA). Viability of cells was determined by SytoxBlue (Life Technologies, USA) stain. 10.000 events of viable cells were analyzed from individual experiments (n=3) to calculate x-fold MFI over background and displayed as mean ± SEM.
Rhesus monkey lymphocytes were stained from whole blood samples by incubation with a cocktail of conjugated mouse anti-human CD3-APC.Cy7 (clone HIT3a), anti-human CD20-FITC (clone 2H7; both BioLegend, USA) and anti-human CD314-APC (clone BAT221; Miltenyi Biotec, Germany) following erythrocyte lysis using ACK lysis buffer (Thermo Fisher Scientific, USA) according to manufacturer's instructions. Cells were measured on a LSRII instrument (BD Bioscience, USA) and analyzed with FlowJo software to calculate the MFI over background.
Protein Expression and Purification
To generate shed MICA (sMICA01), a DNA fragment encoding full length MICA engineered with N-terminal hexa histidine-tag was cloned into the tet-on vector pES.1-T6-PGKPuro (kindly provided by Dr. Manuel Grez, Georg-Speyer-Haus, Frankfurt am Main, Germany). UKF-NB3 (human neuroblastoma) cells kindly provided by Dr. Ulrike Koehl (MHH, Hannover, Germany) were maintained in IMDM medium (Life Technologies, USA) supplemented with 10% FCS (PAA and PAN Biotech, Germany) and 1% Penicillin/Streptomycin (Life Technologies, USA). UKF-NB3 cells were co-transfected with the plasmids pES.1-T6-PGKPuro-MICA01 and pES1-2(M2N) (M2, rtTA) using the Neon transfection system (Life Technologies, USA). Cells were selected with 0.25 mg/ml G418 and 1 µg/ml puromycin (Life Technologies, USA). MICA expression was induced by addition of 2 µg/ml doxycycline (Sigma, Germany). Cells were stressed by serum starvation for 72 h to induce MICA shedding. sMICA was purified with Protino Ni-NTA agarose (Macherey-Nagel, Germany) from dialyzed cell culture supernatant and concentrated using Amicon centrifugal filter units with a molecular weight cut-off of 10 kDa.
To generate soluble MICA (sMICA*04), the DNA sequence encoding the MICA*04 ectodomain (aa 23-299) engineered with a C-terminal hexahistidin-tag was cloned into the pFUSE-hIgG1-Fc2 vector (InvivoGen, USA) containing an IL-2 secretion sequence. HEK293T/17 cells (CRL-11268, human embryonic kidney cells) were purchased from the American Type Culture Collection (ATCC) and maintained in DMEM medium (Life Technologies, USA) supplemented with 10% FCS (PAA and PAN Biotech, Germany), 1% Penicillin/Streptomycin (Life Technologies, USA), 2 mM L-Glutamine (Life Technologies, USA). HEK293T/17 cells were transiently transfected using the polyethyleneimine method (4) . Secreted sMICA*04 was purified with Protino Ni-NTA agarose and subsequent size exclusion chromatography (SEC) on a HiLoad 16/60 Superdex200 column (GE Healthcare, UK) in PBS using an ÄKTA FPLC system (GE Healthcare, UK). Elution fractions containing the sMICA*04 protein were concentrated using Amicon centrifugal filter units with a molecular weight cut-off of 10 kDa.
Deglycosylation Assay
To check for glycosylation, sMICA*04 was treated with either peptide-N-glycosidase F (PNGaseF) to remove N-linked glycans, or protein deglycosylation mix (both New England Biolabs, USA) for removal of N-and O-linked oligosaccharides according to the manufacturer's protocol. Deglycosylation was analyzed by molecular mass reduction via SDS-PAGE and immunoblot with mouse anti-MICA antibody (MAB1300; R&D Systems, USA) and anti-mouse IgG HRP-conjugated secondary antibody (Sigma-Aldrich, USA). Recombinant MICA*04 produced from E.coli as previously described (5) served as nonglycosylated control.
Peptide Spot Arrays
Peptide spot arrays of human MICA (Q29983 aa23-308; 18 amino acid peptides; off-set by 4 amino acids) were synthesized by Fmoc chemistry at activated PEG spacers on cellulose membranes by automated parallel peptide synthesis on a MultiPep RS instrument (Intavis, Germany) and used for binding experiments as described previously (6, 7). After blocking with 5% milk/TBS-T, peptide membranes were incubated with anti-MICA antibody (clone AMO1). Peptide membranes were analyzed by chemiluminescence imaging after incubation with anti-mouse IgG HRP-conjugated antibody (Sigma-Aldrich, USA).
Rhesus Antibody Detection
For the analysis of anti-MICA monkey IgG/IgM antibodies the animals' plasma were analyzed three weeks after sMICA*04 injection. Therefore, ELISA plates were coated with sMICA*04, blocked with BSA blocking solution (Candor, Germany) and probed with rhesus macaque plasma in different dilutions and subsequent washing steps with 0.05% Tween20-PBS. Bound antibodies were detected with either anti-monkey-IgG (SAB3700766) or antimonkey-IgM (SAB3700780) HRP-conjugated antibodies (both Sigma-Aldrich, USA). Following visualization with TMB substrate (KPL, Germany), signals were measured in a microtiter plate reader (λ = 450 nm) and analyzed with Prism 6 software (GraphPad, USA). Data of plasma samples were calculated as mean ± SEM. 
18mer peptide sequence (MICA; Q29983; aa 23-308; 18:4) 
